Expert Review of Pharmacoeconomics & Outcomes Research

Papers
(The H4-Index of Expert Review of Pharmacoeconomics & Outcomes Research is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
How to create value with constrained budgets in oncological care? A narrative review64
Social care data in the UK; current landscape, challenges, and future recommendations49
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment46
Indication-based pricing of the pharmaceuticals in Croatia: case-study42
Adherence to augmentation therapy for the treatment of major depressive disorder41
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology30
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia19
Cost per responder analysis of lebrikizumab versus tralokinumab in moderate to severe atopic dermatitis from a United States perspective16
Cost-effectiveness of mechanical thrombectomy versus intravenous thrombolysis in acute ischemic stroke: a systematic review15
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study14
The value of cycleways to improve population physical activity levels: a systematic review of economic evaluations14
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency13
The role of insurance policies in the drug pricing landscape13
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data13
0.10786914825439